Metabolic and neuropathic outcomes following combined sodium-glucose cotransporter-2 inhibitor therapy and adjunctive acupuncture in obese patients with diabetic neuropathy: a case series
Abstract
Obesity and type 2 diabetes mellitus (T2DM) are associated with chronic metabolic dysregulation and microvascular complications, including diabetic peripheral neuropathy (DPN). This case series describes metabolic and patient reported outcomes during ongoing empagliflozin therapy with adjunctive acupuncture treatment.
The prospective observational case series included three adult participants with obesity, T2DM, and symptom defined DPN. All participants received empagliflozin 10 mg daily for at least 4 weeks before enrollment and continued treatment while receiving standardized acupuncture twice weekly for 10 weeks. Primary outcomes included body weight, body mass index (BMI), and waist circumference. Secondary outcomes included neuropathic pain intensity assessed using the visual analogue scale (VAS), sleep quality measured by a single-item sleep quality score, and fatigue assessed using the fatigue severity scale were recorded at baseline and week 10.
All participants completed the intervention without adverse events. The body weight decreased by 4–9 kg, BMI by 1.2–3.5 kg/m
2
, and waist circumference by 5–10 cm. VAS reduction range from 2 to 4 points, sleep quality and fatigue scores also improved consistently in all cases. Exploratory outcomes indicated enhanced mobility, reduced nocturnal neuropathic symptoms, and high treatment tolerability.
Combined therapy with SGLT2 inhibitors and acupuncture was associated with improvements in metabolic, neuropathic, and functional…
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.